Associate Member 
Department of Immunology
Roswell Park Cancer Institute
Elm and Carlton Streets
Buffalo, NY 14263
Tel: (716) 845-4375
Fax: (716) 845-8906
E-mail: scott.abrams@roswellpark.org 

Lab website: www.roswellpark.org/abrams_lab

Current Program

• Defining cellular and molecular mechanisms of T cell-mediated antitumor activity in vivo
• Identifying tumor escape mechanisms, with emphasis on apoptotic resistance
• Developing novel combination immunotherapies that target or modulate such neoplastic deficiencies

Click here to view the PubMed list of Dr. Abrams' publications.

Profile

Dr. Scott Abrams joined the Faculty of Roswell Park Cancer Institute (RPCI) in 2008 as an Associate Member in the Department of Immunology.  He is also an Associate Professor of Oncology at RPCI, and holds an appointment as Research Associate Professor on the Graduate Faculty at SUNY-Buffalo.

Dr. Abrams came to RPCI from the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, MD, where he served as an Investigator since 1998.  He has been honored by the NCI with five consecutive Performance Awards from 2003 – 2007, and served as a member of several Interest and Working Groups at the National Institutes of Health (NIH) including Immunology, Cytokine, Apoptosis and Vaccine.  Dr. Abrams is the recipient of six NIH Federal Technology Transfer Awards for the discovery of human T lymphocyte peptide epitopes reflecting ras codon 12 mutations.  The identification of such mutated ras peptide sequences has also culminated in patent approval in Europe and is pending approval in the U.S.

Dr. Abrams earned his doctoral degree in Microbiology and Immunology at Indiana University School of Medicine, Indianapolis, IN, and completed a postdoctoral fellowship in the Department of Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, MO.  He then served as Senior Staff Fellow at the NCI before attaining his appointment as Investigator. 

Dr. Abrams’ research interests include defining cellular and molecular mechanisms of T cell-mediated antitumor activity in vivo; identifying tumor escape mechanisms, with emphasis on apoptotic resistance; and developing novel combination immunotherapies that target or modulate such neoplastic deficiencies. 

Dr. Abrams is a member of the American Association for Cancer Research, American Association of Immunologists, Sigma Xi Society, and the International Society for Biological Therapy of Cancer.

Dr. Abrams has authored or co-authored more than 80 journal articles, reviews and book chapters, and has received a number of national and international invitations to speak.   He serves as a reviewer for a number of scientific and biomedical journals, including the Journal of Immunology, Cancer Research, Journal of Immunotherapy and Clinical Cancer Research.